Form Bio

Name: Form Bio
Brand: Form Bio

AI Native

Leading provider of AI-powered solutions for genetic medicine and genome engineering.

Est 2022|Valuation $116.3M|Raised $64M

LinkedIn 7K|Web traffic 1K|FTEs 36|HQ San Francisco, us

- Form Bio vs DNAnexus / Seven Bridges: The latter are longer-established in genomics analysis. Form Bio differentiates through gene therapy-specific functionality (genome integrity, vector/payload design, codon optimization) and an emphasis on applied AI, but it may be less proven in large-scale enterprise deployments. - Form Bio vs Benchling: Benchling is primarily an R&D system-of-record (ELN/LIMS/registry) with some computational tooling; Form Bio is more focused on computational pipelines and omics workflows. - DIY pipelines: Organizations that run Nextflow/WDL pipelines on cloud directly can achieve flexibility and cost control if they have strong platform engineering, but they may forego vendor-provided usability, governance interfaces, and scientific support.

01Competitive Landscape

Narrative analysis

Form Bio vs DNAnexus / Seven Bridges: The latter are longer-established in genomics analysis. Form Bio differentiates through gene therapy-specific functionality (genome integrity, vector/payload design, codon optimization) and an emphasis on applied AI, but it may be less proven in large-scale enterprise deployments.
Form Bio vs Benchling: Benchling is primarily an R&D system-of-record (ELN/LIMS/registry) with some computational tooling; Form Bio is more focused on computational pipelines and omics workflows.
DIY pipelines: Organizations that run Nextflow/WDL pipelines on cloud directly can achieve flexibility and cost control if they have strong platform engineering, but they may forego vendor-provided usability, governance interfaces, and scientific support.

	Form Bio	DNAnexus	Benchling
Starting Price	Published usage-based pricing available from the vendor	Varies (consumption + services; often enterprise)	Custom quotes; pricing not directly listed
Best For	Teams needing managed workflows with applied AI for gene therapy/genome engineering use cases	Large-scale genomics programs requiring enterprise-grade analysis environments	R&D organizations centralizing experimental data (ELN/LIMS/registry)
Key Strength	Gene therapy/AAV-focused positioning + AI-driven sequence tools + Google Cloud alignment	Established enterprise genomics platform with experience in regulated contexts	Strong lab informatics and R&D data standardization; broad biotech adoption
Key Weakness	Limited public third-party reviews; security attestations not clearly public; vendor maturity risk	Can be complex and enterprise-focused; pricing often non-transparent	Less focused on heavy compute pipeline execution for omics compared with pure analysis platforms

Form Bio

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map